Evidence map›Paper›PMID 31388696›Full record

SynthesisOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2019

Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF).

M Hiligsmann, D Cornelissen, B Vrijens, B Abrahamsen, N Al-Daghri, E Biver, M L Brandi, O Bruyère, N Burlet, C Cooper and 16 more

Open access · hybridAbstract readSystematic Review
In one paragraph

Synthesis in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 6 pooled it
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 6 syntheses or guidelines pooled it, 112 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Comparing medication adherence in patients receiving bisphosphonates for preventing fragility fractures: a comprehensive systematic review and network meta-analysis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2022
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Interventions to improve adherence to anti-osteoporosis medications: an updated systematic review.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2020
    Pooled it
  7. Trial
  8. Trial
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Adherence to secondary fracture prevention is associated with reduced risk of subsequent fractures.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025
    Article
  16. Article
  17. Article
  18. Sequential and Long-term Therapy for Osteoporosis.Current osteoporosis reports · 2025
    Review
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 17 institutions in 14 countries.

M HiligsmannDepartment of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, P.O. Box 616, 6200 MD, Maastricht, the Netherlands. m.hiligsmann@maastrichtuniversity.nl.
D CornelissenDepartment of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, P.O. Box 616, 6200 MD, Maastricht, the Netherlands.
B VrijensResearch and Development, AARDEX Group and Department of Public Health, University of Liège, Liege, Belgium.
B AbrahamsenOpen Patient Data Explorative Network, Institute of Clinical Resesarch, University of Southern Denmark, Odense, Denmark.
N Al-DaghriChair for Biomarkers of Chronic Diseases, Biochemistry Department, College of Science, King Saud University, Riyadh, Saudi Arabia.
E BiverDivision of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.
M L BrandiFirmoLab, Fondazione FIRMO e Università di Firenze, Florence, Italy.
O BruyèreDivision of Public Health, Epidemiology and Health Economics, Liège, Belgium and WHO Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Aging, University of Liège, Liege, Belgium.
N BurletGlobal Head of Patient Insights Innovation, Patient Solution Unit, Sanofi, Lyon, France.
C CooperMRC Lifecourse Epidemiology Unit, Southampton General Hospital, University of Southampton, Southampton, UK.
B CortetDepartment of Rheumatology and EA 4490, University-Hospital of Lille, Lille, France.
E DennisonMRC Lifecourse Epidemiology Unit, Southampton General Hospital, University of Southampton, Southampton, UK.
A Diez-PerezMusculoskeletal Research Unit, IMIM-Parc Salut Mar, CIBERFES, Universitat Autònoma de Barcelona, Barcelona, Spain.
A GasparikDepartment of Public Health, University of Medicine, Pharmacy, Science and Technology of Targu Mures, Targu Mures, Romania.
A GrossoPatient partner, Geneva, Switzerland.
P HadjiFrankfurt Centre of Bone Health, Frankfurt, Germany & Philips-University of Marburg, Marburg, Germany.
P HalboutInternational Osteoporosis Foundation, Nyon, Switzerland.
J A KanisCentre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK.
J M KaufmanDepartment of Endocrinology, Ghent University Hospital, Ghent, Belgium.
A LaslopScientific Office, Austrian Federal Office for Safety in Health Care, Vienna, Austria.
S MaggiCNR Aging Branch-NI, Padua, Italy.
R RizzoliDivision of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.
T ThomasDepartment of Rheumatology, Hôpital Nord, CHU Saint-Etienne, Saint-Etienne and INSERM U1059, Université de Lyon-Université Jean Monnet, Saint-Etienne, France.
S TuzunDepartment of Physical Medicine and Rehabilitation, Cerrahpaşa Medical Faculty, İstanbul University Cerrahpaşa, Istanbul, Turkey.
M VlaskovskaMedical Faculty, Department of Pharmacology, Medical University Sofia, Sofia, Bulgaria.
J Y ReginsterChair for Biomarkers of Chronic Diseases, Biochemistry Department, College of Science, King Saud University, Riyadh, Saudi Arabia.
University of Liège · BEMaastricht University · NLUniversity Hospital of Geneva · CHAustralian Catholic University · AUAustrian Agency for Health and Food Safety · ATGhent University Hospital · BEHolbæk Sygehus · DKIstanbul University-Cerrahpaşa · TRKing Saud University · SAMedical University of Sofia · BGMRC Lifecourse Epidemiology Unit · GBPhilips (Germany) · DESanofi (France) · FRUniversitat Autònoma de Barcelona · ESUniversitatea de Medicină, Farmacie, Științe și Tehnologie „George Emil Palade” din Târgu Mureș · ROUniversité Claude Bernard Lyon 1 · FRUniversity of Southampton · GB

Funding

ESCEO -Medical Research Council G0400491Medical Research Council MC_U147585819Medical Research Council MC_U147585824Medical Research Council MC_U147585827Medical Research Council MC_UP_A620_1014Medical Research Council MC_UU_12011/1Versus Arthritis 19583
6 · The paper itself

Abstract

Many patients at increased risk of fractures do not take their medication appropriately, resulting in a substantial decrease in the benefits of drug therapy. Improving medication adherence is urgently needed but remains laborious, given the numerous and multidimensional reasons for non-adherence, suggesting the need for measurement-guided, multifactorial and individualized solutions.

introductionPoor adherence to medications is a major challenge in the treatment of osteoporosis. This paper aimed to provide an overview of the consequences, determinants and potential solutions to poor adherence and persistence to osteoporosis medication.

methodsA working group was organized by the European Society on Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal diseases (ESCEO) to review consequences, determinants and potential solutions to adherence and to make recommendations for practice and further research. A systematic literature review and a face-to-face experts meeting were undertaken.

resultsMedication non-adherence is associated with increased risk of fractures, leading to a substantial decrease in the clinical and economic benefits of drug therapy. Reasons for non-adherence are numerous and multidimensional for each patient, depending on the interplay of multiple factors, suggesting the need for multifactorial and individualized solutions. Few interventions have been shown to improve adherence or persistence to osteoporosis treatment. Promising actions include patient education with counselling, adherence monitoring with feedback and dose simplification including flexible dosing regimen. Recommendations for practice and further research were also provided. To adequately manage adherence, it is important to (1) understand the problem (initiation, implementation and/or persistence), (2) to measure adherence and (3) to identify the reason of non-adherence and fix it.

conclusionThese recommendations are intended for clinicians to manage adherence of their patients and to researchers and policy makers to design, facilitate and appropriately use adherence interventions.

Indexed as

Medication AdherenceConsensusEuropeFractures, BoneGroup ProcessesHumansMusculoskeletal DiseasesOsteoarthritisOsteoporosisPatient Education as TopicPractice Guidelines as TopicRisk FactorsSocieties, MedicalAdherenceDeterminantsOsteoporosisPersistenceSolutions

Identifiers

PMID31388696
PMCPMC6811382
OpenAlexW2969104249

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.